art-header-clip
ExploreTrial

                                                  btnGotoERCF

EXPLORE COMPLETED!!!!

304 patients enrolled!

News

                    Explore drinks at EuroPCR 2013              

foto euroPCR

Over 200 of the total inclusion rate of 300!

This calls for a special celebration at EuroPCR on Wednesday (22/05) afternoon. 

 

Please join us at cafe La Maison,28 Place Sain Ferdinand, 75017 Paris. We expect to complete the study cohort in September 2014. 

 

 

Accepted publication

The manuscript titled: ''The Impact of Multivessel Disease With and Without a Coexisting Chronic Total Occlusion on Short and Long Term Mortality in ST-elevation Myocardial Infarction Patients With and Without Cardiogenic Shock'' has now been accepted in the European Journal of Heart Failure.

 

Abstract

Aims: To evaluate the impact of multivessel disease (MVD) with and without a chronic total occlusion (CTO) on early and late mortality in ST-elevation myocardial infarction (STEMI) patients with and without cardiogenic shock (CS).

Methods and Results: 5018 STEMI patients were treated with primary percutaneous coronary intervention and stratified according to the presence of CS and the extent of coronary artery disease into single vessel disease (SVD), MVD without a CTO and MVD with a CTO. We performed a landmark mortality analysis up to 5-year follow-up with a landmark set at 30 days. In patients without CS (n=4409), only MVD with a CTO was an independent predictor for 30-day (HR:2.8,p<0.01) and 5-year mortality (HR:1.7,p<0.01), whereas MVD without a CTO was not associated with increased mortality. In CS patients (n=609), MVD with and without a CTO were independent predictors for 30-day mortality (HR:2.2,p<0.01, HR:1.8,<0.01). In 30-day CS survivors, only MVD with a CTO was associated with a trend towards increased mortality (HR:1.7,p=0.06).

The proportion of CS patients with a LVEF ≤ 40% was 24% for SVD, 44% for MVD without a CTO and 42% for MVD with a CTO.  In patients without CS, MVD with a coexisting CTO was more often associated with LVEF ≤ 40% in comparison to patients with MVD without a CTO or SVD whereas in patients with CS, MVD with and without a CTO were both more often associated with LVEF ≤ 40% in comparison to patients with SVD.

 

 

 

 

 

 

Conclusion: In non-CS STEMI patients with MVD, the presence of a coexisting CTO in a non-IRA drives early and late mortality. In patients with CS, MVD with and without a CTO were predictors for short term mortality.

 kaplan meierpicture111125

 CScox regression

 figure 2 111209